CERo Therapeutics Holdings, Inc has shared a Phase 1 update showing an AML patient proceeding to stem cell transplant after CER-1236 treatment.

Clinical laboratory setting showing engineered T cell therapy process with schematic overlay of AML cells and stem cell transplant pathway

CERo Therapeutics Holdings, Inc has reported an interim clinical update from its ongoing Phase 1 CERTAIN-T study of CER-1236 in patients with hematologic malignancies, highlighting a single acute myeloid leukemia (AML) case in which a patient proceeded to allogeneic stem cell transplantation following treatment.

The update comes from a very small dataset, with six patients treated to date, and should be interpreted as early safety and feasibility information rather than evidence of efficacy. The company is advancing dose escalation within the study while continuing to monitor pharmacokinetic and pharmacodynamic activity of CER-1236, an engineered T cell therapy designed to engage phagocytic mechanisms in malignant cells.

In the reported case, the fifth patient treated in the trial had multiple refractory AML and had not previously achieved sufficient disease control to enable transplant prior to enrolment. Following infusion of CER-1236 at a total dose of 4 million cells/kg, bone marrow blast levels were reported at 14% on Days 14 and 28, and 7% on Day 42. The patient subsequently underwent allogeneic stem cell transplantation on Day 71.

The transplant event is being viewed by the company as a potentially meaningful clinical trajectory, although no direct causal link has been established between CER-1236 administration and transplant eligibility. The patient’s longer-term outcome remains under evaluation.

CEO Chris Ehrlich said the company is continuing to observe early signals across the programme, stating: “We continue to observe encouraging findings from the ongoing trial, with investigators reporting clinical improvement in two patients treated across the first two cohorts. Although formal response assessments remain ongoing, investigators have reported findings suggestive of clinical benefit following treatment with CER-1236. We look forward to continuing dose escalation and further evaluating CER-1236 in the ongoing Phase 1 study.”

From a safety perspective, the company reiterated that no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), dose-limiting toxicities (DLTs), or treatment-related severe adverse events were observed during the DLT assessment window across treated patients. This continues to position the programme as relatively well tolerated at early dose levels, although the patient numbers remain extremely limited.

The study has now progressed into its third planned cohort, which is expected to evaluate a target dose of one billion cells per patient. The expansion also broadens the patient population to include myelodysplastic syndromes (MDS) and myelofibrosis (MF), alongside AML subtypes already under evaluation. These additions reflect an attempt to test CER-1236 across a wider spectrum of myeloid malignancies where treatment options remain limited and outcomes are often poor.

While the update contains several potentially encouraging signals, including post-treatment disease modulation and a bridge-to-transplant pathway in one patient, the dataset is still far too small to draw meaningful conclusions. Early Phase 1 studies of this nature typically generate hypothesis-forming observations rather than definitive clinical evidence, and the absence of a control arm further limits interpretability.

Overall, the announcement is best characterised as a routine but slightly noteworthy Phase 1 safety and early activity update. The transplant case provides a narrative highlight, but it does not yet establish a reproducible therapeutic effect. The programme will need additional patient cohorts and more mature response data to determine whether the early signals translate into clinically meaningful outcomes.

CERo continues dose escalation as it seeks to better define the safety profile and biological activity of CER-1236 across multiple myeloid malignancy settings.